![]() |
Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours
Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.
More... |
| All times are GMT -7. The time now is 06:24 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021